Logo

Alkermes Reports Results of Lybalvi in P-IIIb (ENLIGHTEN-Early) Study for the Treatment of Schizophrenia or Bipolar I Disorder

Share this

Alkermes Reports Results of Lybalvi in P-IIIb (ENLIGHTEN-Early) Study for the Treatment of Schizophrenia or Bipolar I Disorder

Shots:

  • The P-IIIb (ENLIGHTEN-Early) study evaluates Lybalvi vs olanzapine in a ratio (1:1) in 428 adults aged ≥16 & <40yrs. with schizophrenia or bipolar I disorder who were early in the illness
  • The study met its pre-specified 1EPs i.e., patients achieved less weight gain @12wks., mean percent change from baseline body weight (6.77% vs 4.91%) & the results were consistent with the (ENLIGHTEN-2) study. In 2EPs, patients gained ≥10% & ≥ 7% baseline body weight @3mos. (21.9% vs 30.4%) & (33.1% vs 44.8%), improvement in symptoms, AEs (63.5% & 63.3%)
  • The therapy is approved for schizophrenia & bipolar I disorder as a maintenance monothx. The company plans to submit results to a peer-reviewed journal

Ref: Alkermes | Image: Trading View

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions